BioTuesdays

Category - Markets

Bellerophon Therapeutics
Markets

Ladenburg starts Bellerophon at buy

Ladenburg Thalmann initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.18 on April 13. Bellerophon is developing and optimizing...

April 17, 2017
Reata Pharma
Markets

Ladenburg starts Reata at buy

Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12. Reata focuses on development of small molecule drugs for...

April 13, 2017
Auris Medical
Markets

Roth starts Auris Medical at buy

Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price...

April 13, 2017
Cidara Therapeutics Logo
Markets

Ladenburg starts Cidara at buy

Ladenburg Thalmann launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $11.25 price target. The stock closed at $6.95 on March 11. “We view Cidara as a balanced portfolio of infectious disease...

April 12, 2017
Akari Therapeutics Logo
Markets

WB starts Akari Therapeutics at OP

William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5. Akari is focused on the development of next-generation complement inhibitors for...

April 6, 2017
Markets

HCW ups SteadyMed price target to $15

H.C. Wainwright raised its price target for SteadyMed (NASDAQ:STDY) to $15 from $10 after the Patent Trial and Appeal Board ruled in favor of SteadyMed in an inter partes review (IPR) proceeding against United...

April 3, 2017
Calithera Biosciences
Markets

Leerink resumes coverage of Calithera at OP

Leerink resumed coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating and a $16 price target, saying the company is well positioned to execute with multiple sources of upside. The stock closed at...

April 3, 2017
Galectin Therapeutics
Markets

HCW upgrades Galectin to buy

H.C. Wainwright upgraded Galectin Therapeutics (NASDAQ:GALT) to “buy” from “neutral” and raised its price target to $3 from 60 cents, citing a more positive view of the therapeutic potential of the mechanism of galectin...

March 30, 2017
Calithera Biosciences
Markets

HCW ups Calithera price target to $14

H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on...

March 29, 2017
Verastem
Markets

HCW ups Verastem price target to $6.50

H.C. Wainwright raised its price target for Verastem (NASDAQ:STM) to $6.50 from $5, ahead of a highly anticipated top-line readout from the Phase 3 DUO study of duvelisib for the treatment of relapsed/refractory chronic...

March 24, 2017